Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olmutinib as First-Line Therapy in EGFR-Mutated NSCLC
NCT02444819Phase 2Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Mar 2015
- Primary completion
- Aug 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of olmutinib in non-small cell lung cancer (NSCLC), sponsored by Hanmi Pharmaceutical. Started Mar 2015; status: completed.
02
Drugs
olmutinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02444819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02444819.